Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MT-ND4 | P03905 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056618 | 0.92 | CYP3A4 (0.63) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL47262 | 0.92 | CYP3A4 (0.63) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL10280019 | 0.92 | CYP3A4 (0.63) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL13056524 | 0.87 | CYP3A4 (0.51) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL16202237 | 0.82 | CYP3A4 (0.48) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL15315417 | 0.82 | CYP3A4 (0.69) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL17211597 | 0.82 | CYP3A4 (0.42) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL13056515 | 0.80 | CYP3A4 (0.84) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL10133744 | 0.80 | CYP3A4 (0.59) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL2631491 | 0.79 | CYP3A4 (0.58) | CYP3A4MAPTSMN1; SMN2ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9103822-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9017954-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140323336-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140243236-A1 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130273565-A1 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8486620-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8445191-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-02 | — | — | US | disclosed |
| US-20110245098-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110244545-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110244544-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110244545-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | FCGR2A, CD68, CA14 | CYP3A4 1601/4885MAPT 4554/4885SMN1; SMN2 4326/4885 |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | CYP3A4 33/4885MAPT 2927/4885SMN1; SMN2 4647/4885 |
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | TYR, TH, TYRO3 | CYP3A4 5/4885MAPT 4799/4885SMN1; SMN2 4698/4885 |
| US-20140243236-A1 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION | FCGR2A, CD68, CA14 | CYP3A4 1601/4885MAPT 4554/4885SMN1; SMN2 4326/4885 |
| US-20110244544-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | FCGR2A, CD68, CA14 | CYP3A4 1601/4885MAPT 4554/4885SMN1; SMN2 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.